Atai: Following the path that Spravato laid and moving beyond it

Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40).

Show Notes:
Psychedelic Stocks: Focus On Their Cash
Deep Dive: Atai Life Sciences
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged

Read our episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions